Novo Nordisk’s Adiposity Franchise Under Siege as CVS Levels the Playing Field and US Pricing Rules Tighten
02.06.2026 - 19:42:07 | boerse-global.de
Novo Nordisk is facing a double blow to its once-dominant position in the US weight-loss market. The Danish drugmaker lost its preferred formulary status at CVS Caremark on 1 June 2026, just as new government pricing agreements are compressing margins across the GLP-1 therapy segment. The combined pressure has sent shares sliding further as investors weigh how the company will defend its franchise without the commercial edge that previously supported Wegovy.
CVS Caremark, one of the largest pharmacy benefit managers in the United States, has now placed Eli Lilly’s Foundayo and Zepbound on equal footing with Wegovy. The move ends the preferential listing that gave Novo Nordisk a distinct advantage in securing prescriptions and reimbursements within the CVS network. Foundayo, an oral therapy, gained parity immediately on 1 June, while Zepbound will follow on 1 October. Physicians and payers will now make decisions on clinical outcomes and patient preferences rather than formulary tiering.
The Novo Nordisk ADR fell 3.41 percent on the day the change took effect, a sharper decline than the 1.97 percent average drop recorded across the pharmaceuticals and medical research sector. The stock now trades at €36.98 on a closing basis, roughly 17 percent below where it started the year and 42 percent lower than twelve months ago. From its 52-week high of €70.13 in June 2025, the equity has shed 47 percent. On Tradegate the shares recently changed hands at €37.78, leaving them down 15.44 percent year?to?date and 40.59 percent over the past year.
The company’s first?quarter results for 2026 offered a mixed picture. Earnings per share came in at $1.04, comfortably ahead of the analyst consensus of $0.87, while revenue of $10.85 billion was almost exactly in line with the $10.86 billion forecast. The oral version of Wegovy has racked up more than 2 million prescriptions since its US launch in January, roughly double the initial expectations. Despite those bright spots, management raised its full?year guidance only to forecast a decline in both adjusted revenue and operating profit. Analysts point to three principal reasons for the share slump: intensifying competition in the GLP?1 segment, the loss of the CVS formulary advantage, and the prospect of a profit contraction even as sales of Wegovy and related products continue to expand.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
A new layer of pricing pressure has emerged from Washington. Recent US government pricing agreements based on the most?favored?nation principle are pushing monthly out?of?pocket costs for obesity therapies below $350. That improves patient access but squeezes manufacturer margins. Novo Nordisk is responding by expanding its own digital direct?to?consumer channels, aiming to reach patients outside traditional insurance?based models. The strategy reflects a broader shift in the GLP?1 market, where revenue streams are becoming both more political and more transparent.
Against this difficult backdrop, Novo Nordisk is pressing ahead with a substantial share buy?back programme. Launched on 4 February 2026, the scheme allows for the repurchase of B?shares worth up to 15 billion Danish kroner over twelve months. A tranche opened on 6 May 2026 under EU market?abuse rules runs until 1 February 2027 and covers B?shares with a maximum value of 11.2 billion kroner. As of 29 May the company had bought 17,889,179 B?shares at an average price of 263.47 kroner each, for a total outlay of roughly 4.71 billion kroner. Late?May purchases added nearly 840,000 shares at prices ranging between 286.16 and 293.42 kroner. Novo Nordisk now holds 35,074,480 own B?shares, equivalent to 0.8 percent of total share capital. While buy?backs can support earnings per share, they do not address the operational questions around pricing, competition and pipeline depth.
The analyst consensus on the stock remains a “Hold”, with some experts cautioning that weaker free?cash?flow conversion and higher leverage are weighing on valuation. The key question for investors is whether Novo Nordisk can hold its ground against Eli Lilly now that the formulary advantage has disappeared.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
The next major catalyst arrives between 5 and 8 June at the American Diabetes Association’s Scientific Sessions in New Orleans. Novo Nordisk will present 40 abstracts, with the spotlight falling on Phase 3 data from the REIMAGINE?1?3 studies of CagriSema — a weekly injection that combines the amylin analogue cagrilintide with the GLP?1 receptor agonist semaglutide. The target indications are type?2 diabetes, obesity and weight management. On Sunday 7 June the company will host a dedicated investor event covering the ADA abstracts and other pipeline candidates, including the once?weekly injectable Zenagamtide. The data will be crucial in demonstrating whether the next generation of products can sustain the growth story in a market where pricing has become far more hostile and competitive threats are multiplying.
Ad
Novo Nordisk Stock: New Analysis - 2 June
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
